AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9404870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 1789763 — intervention group
Group type: EXPERIMENTAL
Intervention: Valiant‐PhD alloy
Number of subjects: 73
Study 1789763 — intervention group
Group type: COMPARATOR
Intervention: Lojic N alloy
Number of subjects: 73
Study 7059561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilean mixed diet at protein levels of 0.40, 0.55, and 0.70 g/kg body-weight per day
Number of subjects: 8
Study 7059561 — intervention group
Group type: COMPARATOR
Intervention: Egg reference diet providing 0.30, 0.45, and 0.60 g protein/kg per day
Number of subjects: 8
Study 7059561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilean mixed diet
Number of subjects: 8
Study 7059561 — intervention group
Group type: COMPARATOR
Intervention: Egg diet
Number of subjects: 8
Study 29543548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcaftadine 0.25%
Number of subjects: 240
Study 29543548 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1%
Number of subjects: 240
Study 29543548 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 240
Study 28689602 — intervention group
Group type: EXPERIMENTAL
Intervention: Malva nut polysaccharide
Number of subjects: 24
Study 28689602 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing gel containing malva nut polysaccharide
Number of subjects: 24
Study 28689602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 24
Study 25724385 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification training of Interpretations (CBM-I)
Number of subjects: 16
Study 25724385 — intervention group
Group type: COMPARATOR
Intervention: Placebo variant of CBM-I
Number of subjects: 16
Study 25888685 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 645
Study 25888685 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived Stigmatization
Number of subjects: 645
Study 25888685 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience (indirect effect)
Number of subjects: 645
Study 24030571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe formulation of canakinumab
Number of subjects: 130
Study 24030571 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted lyophilized formulation of canakinumab
Number of subjects: 130
Study 21383323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 9
Study 19374216 — intervention group
Group type: EXPERIMENTAL
Intervention: COND (circulating-water mattress at 37 degrees C on the back)
Number of subjects: 43
Study 19374216 — intervention group
Group type: EXPERIMENTAL
Intervention: COND + CONV (circulating-water mattress associated with warm air blanket at 42 degrees C over the thorax and upper limbs)
Number of subjects: 43
Study 19374216 — intervention group
Group type: COMPARATOR
Intervention: COND
Number of subjects: 43
Study 19374216 — intervention group
Group type: EXPERIMENTAL
Intervention: COND + CONV
Number of subjects: 43
Study 17001467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine (L-alanyl-L-glutamine 200mg/ml) for 20h at a rate of 0.125ml/kg/h
Number of subjects: 15
Study 17001467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 15336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 20 microg/kg
Number of subjects: 100
Study 15336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 100
Study 15336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 80 microg/kg
Number of subjects: 100
Study 15336470 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 100
Study 15336470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10930822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (AT)
Number of subjects: 39
Study 10930822 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (PV)
Number of subjects: 39
Study 9591517 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day tolcapone
Number of subjects: 379
Study 9591517 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day tolcapone
Number of subjects: 379
Study 9591517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 8023687 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive-compulsive behaviors
Number of subjects: 810
Study 8023687 — intervention group
Group type: EXPERIMENTAL
Intervention: Scores on compulsive, borderline and histrionic personality disorder scales
Number of subjects: 810
Study 2682347 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine treatment
Number of subjects: 13
Study 788768 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic/corticosteroid combination
Number of subjects: 0
Study 788768 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic alone
Number of subjects: 0
Study 788768 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid alone
Number of subjects: 0
Study 30650572 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in a forest for approximately 15 min
Number of subjects: 60
Study 30650572 — intervention group
Group type: COMPARATOR
Intervention: Walking in a city area for approximately 15 min
Number of subjects: 60
Study 28177739 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 304
Study 28177739 — intervention group
Group type: COMPARATOR
Intervention: Combined aerobic and resistance training
Number of subjects: 304
Study 28177739 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 304
Study 28177739 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-exercising control
Number of subjects: 304
Study 24127077 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision concept including débridement, irrigation, and insertion of temporary drainage with hardware retention until healing
Number of subjects: 31
Study 23463779 — intervention group
Group type: EXPERIMENTAL
Intervention: B2A-coated ceramic granules (Amplex)
Number of subjects: 24
Study 23463779 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 24
Study 21240780 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 112
Study 21240780 — intervention group
Group type: COMPARATOR
Intervention: Usual small group lecture (SGL)
Number of subjects: 112
Study 19789014 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound (SUS)
Number of subjects: 442
Study 17052087 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury prevention presentation to the injured child's class
Number of subjects: 0
Study 17052087 — intervention group
Group type: COMPARATOR
Intervention: Injury prevention presentation to the control class
Number of subjects: 0
Study 14663474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 403
Study 14663474 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 5 mg once daily
Number of subjects: 403
Study 14663474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 403
Study 10667628 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face, in-hospital counseling sessions followed by telephone counseling
Number of subjects: 254
Study 10667628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 254
Study 10667628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 254
Study 9245178 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaire with stamped return envelope
Number of subjects: 138
Study 9245178 — intervention group
Group type: COMPARATOR
Intervention: Postal questionnaire with post-free return envelope
Number of subjects: 138
Study 8750218 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycaemic control after 1 year
Number of subjects: 12
Study 8750218 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycaemic control after 3 months
Number of subjects: 12
Study 8750218 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis
Number of subjects: 12
Study 2463912 — intervention group
Group type: EXPERIMENTAL
Intervention: N,N dimethylglycine (DMG) 300 mg/day for the first 14 days, then 600 mg/day
Number of subjects: 19
Study 2463912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 4934374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 62
Study 4934374 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 62
Study 31522631 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician turnover
Number of subjects: 328
Study 29444268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial tobacco product warning labels (TPWLs)
Number of subjects: 0
Study 29444268 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel assessment methods (brain imaging, eye tracking, 'best-worst' discrete choice experiments)
Number of subjects: 0
Study 28663402 — intervention group
Group type: EXPERIMENTAL
Intervention: Localisation system (Group A)
Number of subjects: 126
Study 28663402 — intervention group
Group type: COMPARATOR
Intervention: Conventional means (Group B)
Number of subjects: 126
Study 26674631 — intervention group
Group type: EXPERIMENTAL
Intervention: Average daily moderate-to-vigorous physical activity (MVPA)
Number of subjects: 417
Study 26674631 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood social interaction
Number of subjects: 417
Study 23323573 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED) interventions
Number of subjects: 77
Study 23323573 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 77
Study 23323573 — intervention group
Group type: EXPERIMENTAL
Intervention: All writing conditions (including WED)
Number of subjects: 77
Study 22024518 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 25 mg
Number of subjects: 111
Study 22024518 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 75 mg
Number of subjects: 111
Study 22024518 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 200 mg
Number of subjects: 111
Study 22024518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 22024518 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 (75, 150, or 200 mg) in treatment-experienced patients
Number of subjects: 111
Study 22024518 — intervention group
Group type: COMPARATOR
Intervention: Placebo in treatment-experienced patients
Number of subjects: 111
Study 18200348 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation using commercial electrical devices
Number of subjects: 20
Study 18200348 — intervention group
Group type: COMPARATOR
Intervention: Voluntary physical activity with loads
Number of subjects: 20
Study 16465518 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0
Study 16465518 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised comparisons
Number of subjects: 0
Study 12779258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiation
Number of subjects: 32
Study 12779258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated radiation therapy with a linear accelerator
Number of subjects: 32
Study 12779258 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (comparison group)
Number of subjects: 32
Study 11014390 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 49
Study 11014390 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and fluphenazine
Number of subjects: 49
Study 11014390 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 49
Study 11014390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 9071624 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bifonazole-urea ointment alone
Number of subjects: 120
Study 9071624 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bifonazole-urea ointment combined with oral griseofulvin 500 mg
Number of subjects: 120
Study 9071624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral treatment)
Number of subjects: 120
Study 8219113 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose tobramycin (5 mg/kg per day) plus ceftriaxone (2 g/day) (C + T)
Number of subjects: 92
Study 8219113 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (1.5 mg/kg, every 8 h) plus azlocillin (4 g, every 6 h) (A + T)
Number of subjects: 92
Study 2412051 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (subacute treatment)
Number of subjects: 110
Study 2412051 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (chronic treatment for 3 months)
Number of subjects: 110
Study 2412051 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 110
Study 29477133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and exercise therapy
Number of subjects: 62
Study 29477133 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound and exercise therapy
Number of subjects: 62
Study 26654350 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg amoxicillin and 500 mg metronidazole three times per day for 7 days during the non-surgical treatment phase (T1)
Number of subjects: 80
Study 26654350 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics administered during the surgical phase (T2)
Number of subjects: 80
Study 26654350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 25277807 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 40
Study 25277807 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (placebo group)
Number of subjects: 40
Study 22247273 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS) pacing
Number of subjects: 41
Study 22247273 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacing (dual-chamber pacemaker with conventional algorithms)
Number of subjects: 41
Study 20596067 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery performed by residents
Number of subjects: 3236
Study 20596067 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery performed by specialists
Number of subjects: 3236
Study 18578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cure resin cement
Number of subjects: 48
Study 18578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement
Number of subjects: 48
Study 18578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation at 15 minutes after cementation
Number of subjects: 48
Study 18578178 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation at 24 hours after cementation
Number of subjects: 48
Study 15778466 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min 55 degrees F cool water bath followed by air cooling
Number of subjects: 6
Study 15778466 — intervention group
Group type: COMPARATOR
Intervention: Air cooling
Number of subjects: 6
Study 15778466 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min 55 degrees F cool water bath
Number of subjects: 6
Study 12431867 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) coupled with Bayesian forecasting (D(a))
Number of subjects: 32
Study 12431867 — intervention group
Group type: COMPARATOR
Intervention: Moellering's nomogram (D(M))
Number of subjects: 32
Study 10512926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral calcification in systemic sclerosis patients
Number of subjects: 37
Study 10512926 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched and sex-matched subjects)
Number of subjects: 37
Study 10512926 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of Raynaud's phenomenon in patients
Number of subjects: 37
Study 10512926 — intervention group
Group type: EXPERIMENTAL
Intervention: Age in patients
Number of subjects: 37
Study 7726273 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed questioning about recurrent genital symptoms during pregnancy.
Number of subjects: 201
Study 7726273 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed histories on patients without suggestive symptoms or with somewhat suggestive symptoms.
Number of subjects: 201
Study 7726273 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed histories on subjects with highly suggestive symptoms.
Number of subjects: 201
Study 7726273 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive values for recurrent genital symptoms.
Number of subjects: 201
Study 7726273 — intervention group
Group type: COMPARATOR
Intervention: Asking if the patient has ever had genital herpes.
Number of subjects: 201
Study 2201163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 364
Study 2201163 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 364
Study 6355617 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (F) 40 mg daily for 3 days
Number of subjects: 6
Study 6355617 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (C) 25 mg . 6 hr-1 with Furosemide (F)
Number of subjects: 6
Study 6355617 — intervention group
Group type: COMPARATOR
Intervention: Captopril (C) alone
Number of subjects: 6
Study 6355617 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (F) alone and F + C
Number of subjects: 6
Study 31525489 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month peer mentorship intervention
Number of subjects: 0
Study 31525489 — intervention group
Group type: COMPARATOR
Intervention: Minimally enhanced usual care condition
Number of subjects: 0
Study 29247102 — intervention group
Group type: EXPERIMENTAL
Intervention: Without overstatement
Number of subjects: 622
Study 29247102 — intervention group
Group type: COMPARATOR
Intervention: With overstatement
Number of subjects: 622
Study 25916386 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-PDFF
Number of subjects: 132
Study 24317204 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory pressure of 10 cm H2O (group P10)
Number of subjects: 67
Study 24317204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 15 cm H2O (group P15)
Number of subjects: 67
Study 24317204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 20 cm H2O (group P20)
Number of subjects: 67
Study 24317204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory pressure of 25 cm H2O (group P25)
Number of subjects: 67
Study 22749924 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Score (RS) based on clinical and histopathological features
Number of subjects: 378
Study 19470869 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 11140
Study 19470869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP)
Number of subjects: 11140
Study 19470869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP)
Number of subjects: 11140
Study 19470869 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP)
Number of subjects: 11140
Study 19470869 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved blood pressure values
Number of subjects: 11140
Study 17900460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin prescription
Number of subjects: 28320
Study 15671918 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI or ARB (angiotensin converting enzyme inhibitor or angiotensin receptor blocker)
Number of subjects: 76069
Study 15671918 — intervention group
Group type: COMPARATOR
Intervention: Placebo or reference drug (beta-blocker or diuretic)
Number of subjects: 76069
Study 15671918 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibition (ACEI or ARB)
Number of subjects: 76069
Study 15671918 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs and ARBs
Number of subjects: 76069
Study 15671918 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibition
Number of subjects: 76069
Study 11485111 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for 1 week
Number of subjects: 36
Study 11485111 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP (2 cm H2O with holes in mask)
Number of subjects: 36
Study 11485111 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cognitive functioning posttreatment
Number of subjects: 36
Study 9506593 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with combined streptokinase and tissue plasminogen activator
Number of subjects: 244
Study 8151411 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123-phenylpentadecanoic acid (IPPA) 2 mCi
Number of subjects: 0
Study 8151411 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123-phenylpentadecanoic acid (IPPA) 4 mCi
Number of subjects: 0
Study 8151411 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-123-phenylpentadecanoic acid (IPPA) 6 mCi
Number of subjects: 0
Study 8151411 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3287912 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg once daily for the first two days followed by 20 mg once daily for the remainder of the study (14 days, minimum 7 days, maximum 28 days)
Number of subjects: 1290
Study 3287912 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1290
Study 3287912 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 4 g per day for the duration of the study
Number of subjects: 1290
Study 3287912 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily for two days followed by 250 mg in the morning and 500 mg in the evening thereafter
Number of subjects: 1290
Study 3287912 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg three times per day for two days and 25 mg three times per day thereafter
Number of subjects: 1290
Study 31800559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intense pulsed light and radiofrequency (E‐light)
Number of subjects: 50
Study 31800559 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 50